Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.41 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.41 |
| ▸ | KDR | P35968 | 3/20 | 0.41 |
| ▸ | ATR | Q13535 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.39 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.39 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.38 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.38 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.38 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1396133 | 0.78 | NPSR1 (0.57) | L3MBTL1KDRALDH1A1LMNAHTT | |
| SCHEMBL31359827 | 0.78 | NPSR1 (0.57) | L3MBTL1KDRALDH1A1LMNAHTT | |
| SCHEMBL19806090 | 0.74 | KDM4E (0.58) | L3MBTL1HSD17B1HSD17B2CYP2A6KDR | |
| SCHEMBL1931675 | 0.73 | KDR (0.44) | KDRALDH1A1LMNAHTTNPSR1 | |
| SCHEMBL25379113 | 0.73 | CYP2A6 (0.46) | HSD17B1HSD17B2CYP2A6MKNK1MKNK2 | |
| SCHEMBL30482571 | 0.73 | CYP2A6 (0.46) | HSD17B1HSD17B2CYP2A6MKNK1MKNK2 | |
| SCHEMBL7904780 | 0.73 | ALDH1A1 (0.60) | L3MBTL1ALDH1A1LMNAHTTNPSR1 | |
| SCHEMBL2886889 | 0.72 | PDE4A (0.60) | ALDH1A1LMNANPSR1MAPTHPGD | |
| SCHEMBL1396090 | 0.72 | KMT2A (0.57) | L3MBTL1KDRALDH1A1LMNANPSR1 | |
| SCHEMBL31359722 | 0.72 | KMT2A (0.57) | L3MBTL1KDRALDH1A1LMNANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1922183-B | Nitrogenous fused heteroaromatic ring derivative | BANYU PHARMA CO LTD | 2010-05-26 | — | — | CN | disclosed |
| US-7645756-B2 | 6-[4-(3-piperidin-1-ylpropoxy)-phenyl]-[1,2,4]triazolo[4,3-b]pyridazine; has histamine-H3 receptor antagonistic effect or a histamine-H3 receptor inverse-agonistic effect; for metabolic system, circulatory system or nervous system diseases | BANYU PHARMACEUTICAL CO. LTD. (JP) | 2010-01-12 | — | — | US | disclosed |
| US-20070167453-A1 | Nitrogenous fused heteroaromatic ring derivative | MSD K.K. (JP) | 2007-07-19 | — | — | US | disclosed |
| CN-1922183-A | Nitrogenous fused heteroaromatic ring derivative | BANYU PHARMA CO LTD (JP) | 2007-02-28 | — | — | CN | disclosed |
| EP-1719756-A1 | NITROGENOUS FUSED HETEROAROMATIC RING DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167453-A1 | Nitrogenous fused heteroaromatic ring derivative | HRH3, HRH2, HRH4 | L3MBTL1 2263/4885HSD17B1 2203/4885HSD17B2 1706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.